Indian SME pharma firms see shift of orders from China; cost, quality concerns remain
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Small and mid-sized Indian pharma firms at CPHI Worldwide on Tuesday said they are seeing more orders move from China.
- ✓Western buyers now use India to diversify supply chains due to lower labor costs.
- ✓Clarion Organics Director Vivek Tiwari said, "India continues to hold a cost advantage in both intermediates."
Story at a Glance
- Category
- BUSINESS
- Reported By
- Economic Times
- Reading Speed
- 3 Minute(s)
- Market Focus
- India Economy
Small and mid-sized Indian pharmaceutical firms are witnessing a shift in orders away from China. As Western buyers diversify their supply chains, India benefits from lower labor costs and local raw materials. However, some industry leaders caution about the heavy reliance on Chinese imports for essential components.
MILAN: Small and mid-sized Indian pharmaceutical firms at CPHI Worldwide on Tuesday said they are seeing more orders move from China, particularly for drug intermediates, as Western buyers diversify supply chains, though some cautioned that India still depends on Chinese raw materials and cannot yet match its prices.
CPHI is a major global business-to-business platform for the pharmaceutical industry, bringing together drug manufacturers, API suppliers, Contract Development and Manufacturing Organizations (CDMOs), contract manufacturers, formulation companies and procurement teams.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Economic Times
Read the full, original unfiltered story directly on the publisher's portal.